Visiox Pharma, LLC. , a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases in need of new treatment options, today announced the appointment of Cynthia Matossian , M. Deb. as Main Medical Official.
“Dr. Matossian is an experienced and enthusiastic eye care leader, dedicated to providing compassionate treatment and advancing innovation, ” said Ryan Bleeks , C hief Executive Officer. “Her clinical expertise and proven leadership, as well as her extensive medical and clinical research experience, will further strengthen our efforts and support the progress of our product pipeline. ”
As Chief Medical Officer, Dr. Matossian will certainly play a critical role in developing the medical affairs strategy for the company’s near-term commercial products, as well because helping to forge strategic partnership engagements plus evaluating portfolio expansion.
“I could not be more thrilled to become joining Visiox Pharma and working with such a dynamic management team, ” commented Cynthia Matossian , M. D. “The Company’s lead program, PDP-716 (brimonidine tartrate 0. 35%), has already demonstrated compelling results with a promising safety profile and durability that could change the standard of care for patients along with glaucoma. I believe the same potential exists for SDN-037 (difluprednate 0. 04%) addressing an unmet need for cataract surgery that Visiox plans to file later this year. ”
Dr . Matossian is the Founder and past Medical Director of Matossian Eye Associates started in 1987 with one office plus two employees. Under her leadership, the particular practice grew to 14 doctors and over 90 employees until it was by acquired the private equity backed business entity. Together, in a collaborative effort among the group of eye surgeons, she developed and built a successful freestanding ambulatory surgery center (ASC) leading the way since a pioneer in ASC ownership. Doctor Matossian has authored hundreds of articles, routinely lectures, and has participated in numerous clinical trials. Her list of honors plus awards include Top 100 Women within Ophthalmology Power List, President of the American College of Eye Surgeons and the New York IOL Implant Society, plus President and Board Member for the particular American University of Vision Surgeons (ACES).
Doctor. Matossian earned her medical degree from Hershey Healthcare Center of Pennsylvania State University College associated with Medicine , completed the girl ophthalmology residency at George Washington University School of Medicine , and is fellowship-trained in corneal disease.
Visiox is a privately financed biopharmaceutical company focused on the development plus commercialization of ophthalmic therapeutic candidates in order to address extremely prevalent illnesses in require of brand new treatment choices. Each day is an opportunity for us to disrupt and revolutionize the current market to maximize patient and physician satisfaction. Because an agile business partner, we may achieve this through a high level associated with collaboration with all eye care professionals.
Visiox recently announced the particular submission of a New Drug Application to the U. S. FDA with regard to lead item candidate, PDP-716 (brimonidine tartrate 0. ), which offers the potential to be the first once-daily brimonidine in order to enter the market for the particular treatment of glaucoma.
Visiox programs to submit a second New Drug Application for SDN-037 (difluprednate 0. 04%) towards the U. H. FDA in the coming months to address an unmet need for cataract surgery. SDN-037 is a twice daily topical difluprednate corticosteroid utilizing patented TJMä (Tight Junction Modulation) proprietary formulation. The novel technology provides powerful post-surgical control of inflammation in a clear solution enabling convenient dosing with a proven active ingredient. Cataract extraction is the most frequently performed eye surgical treatment within the U. S. It accounts for 70% of all ocular surgeries. 50 million people are projected to have cataracts within the Oughout. S. simply by 2050 1 .
PDP-716, SDN-037 and TearActä delivery technology were licensed by Visiox from Sun Pharma Advanced Research Company Ltd. For more information, please visit Visiox Pharma or LinkedIn .